Pangaea Oncology S.A.

PANG · MC · Healthcare / Diagnostics & Research

1.47EUR+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close1.47

Open1.47

Day Range1.47 – 1.47

52-Week Range1.43 – 1.75

Volume0

Market Cap51.36M

P/E (TTM)0.00

Forward P/E0.00

EPS-0.11

Dividend Yield0.00%

Beta0.03

50-Day Avg1.51

200-Day Avg1.60

About

Pangaea Oncology, S.A., a precision oncology company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, including mutation analysis in tissue and liquid biopsy; gene amplification and translocation testing; immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH); gene expression profiling and transcriptomic signatures; and tumor mutational burden (TMB) and microsatellite instability and (MSI) assessment services. It also provides diagnostic platforms validation and pre-clinical services. Pangaea Oncology, S.A. was incorporated in 2006 and is based in Zaragoza, Spain.

Company Details

SectorHealthcare
IndustryDiagnostics & Research
CEOMr. Javier Rivela-Rodriguez C.F.A., M.B.A.
Employees165
HeadquartersCalle Coso nº 55, 3º, Zaragoza, Spain, Spain
Websitehttps://www.panoncology.com

Leadership

Mr. Javier Rivela-Rodriguez C.F.A., M.B.A.Co-Founder, CEO & Director
Dr. Rafael Rosell Costa M.D., Ph.D.Chief Scientific Officer, Director, President & Member of Scientific Committee
Alejandro Garcia Moncayo M.B.A.Executive Director of Corporate & CFO
Ms. Carmen AlbiolHead of Operations for IOR
Dr. Miguel Angel Molina B.Sc., Ph.D.Executive Director of Research & Development and Member of Scientific Committee
Alejandro Martinez M.D.Chief Medical Officer & Medical Director at IOR (Hospital Universitari Dexeus)
Cristina Masferrer EMBAChief Business Officer

Financials

Income Statement

Currency: EUR	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	3.09M	1.72M	1.95M	2.52M	2.62M	3.06M	3.32M	4.10M	4.60M	4.37M	8.00M	14.27M	14.52M
Growth (%)	-	-44.40%	+13.52%	+29.17%	+4.11%	+16.65%	+8.44%	+23.61%	+12.29%	-5.11%	+83.12%	+78.41%	+1.78%
Cost of Revenue	-393.56K	-335.76K	-717.95K	-1.89M	-851.69K	-1.23M	-1.09M	-512.72K	-568.61K	255.54K	244.86K	-21.02K	103.97K
Gross Profit	3.48M	2.05M	2.67M	4.41M	3.47M	4.29M	4.41M	4.61M	5.17M	4.11M	7.75M	14.29M	14.42M
Gross Margin	112.74%	119.55%	136.83%	175.11%	132.49%	140.28%	132.93%	112.51%	112.35%	94.15%	96.94%	100.15%	99.28%
Operating Expense	3.27M	3.12M	3.64M	4.95M	6.18M	6.07M	9.20M	6.28M	5.70M	1.55M	10.50M	12.23M	18.06M
Operating Income	209.94K	-1.07M	-974.66K	-542.56K	-2.71M	-1.78M	-4.79M	-1.66M	-532.97K	2.56M	-2.74M	2.06M	-3.64M
Operating Margin	6.80%	-62.09%	-50.00%	-21.55%	-103.31%	-58.29%	-144.51%	-40.60%	-11.58%	58.58%	-34.30%	14.41%	-25.06%
EBITDA	740.37K	-308.96K	558.92K	-231.70K	-903.59K	739.85K	-1.71M	730.31K	146.78K	-1.41M	-1.56M	1.19M	-945.65K
EBITDA Margin	23.97%	-17.99%	28.67%	-9.20%	-34.47%	24.19%	-51.63%	17.81%	3.19%	-32.25%	-19.47%	8.31%	-6.51%
Net Income	77.40K	-196.39K	-486.36K	-594.53K	-1.65M	-1.25M	-4.84M	-1.79M	-641.91K	-2.71M	-4.66M	-1.17M	-3.60M
Net Income Margin	2.51%	-11.44%	-24.95%	-23.61%	-62.82%	-40.96%	-145.96%	-43.77%	-13.94%	-62.09%	-58.22%	-8.18%	-24.76%
R&D	-	-	-	-	-	-	-	-	-	-	1.03M	-	-
R&D as % of Total Revenue	-	-	-	-	-	-	-	-	-	-	12.85%	-	-
Interest Expense	115.78K	118.50K	192.45K	260.25K	295.30K	346.79K	190.78K	186.03K	252.91K	189.41K	133.94K	301.31K	298.26K
Interest Expense % of Total Revenue	3.75%	6.90%	9.87%	10.34%	11.26%	11.34%	5.75%	4.54%	5.49%	4.34%	1.67%	2.11%	2.05%

Balance Sheet

Currency: EUR	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	6.54M	8.46M	11.01M	17.94M	18.96M	20.35M	16.88M	17.17M	20.85M	28.38M	28.83M	32.41M	32.11M
Total Liabilities	4.71M	6.83M	9.95M	11.89M	13.91M	11.74M	8.56M	8.61M	6.76M	5.30M	10.03M	9.57M	10.05M
Total Equity	1.83M	1.63M	1.05M	6.05M	5.05M	8.62M	8.31M	8.57M	14.09M	23.08M	17.82M	22.10M	21.30M
Cash	49.56K	58.81K	95.08K	3.78M	314.32K	667.42K	339.63K	251.48K	2.02M	7.10M	1.38M	3.34M	1.98M
Total Debt	555.50K	2.49M	3.19M	3.56M	12.24M	4.76M	3.72M	6.75M	5.36M	3.49M	5.73M	5.61M	5.82M
Net Debt	505.94K	2.43M	3.10M	-216.91K	11.92M	4.09M	3.39M	6.49M	3.34M	-3.61M	4.35M	2.27M	3.85M

Cash Flow

Currency: EUR	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-659.69K	-1.89M	-2.31M	-1.78M	-6.48M	-2.17M	-2.40M	-1.92M	-2.50M	-3.68M	-2.40M	-4.57M	-2.52M
Investing Cash Flow	-111.07K	-60.02K	-231.90K	-852.65K	-1.05M	-85.66K	-20.30K	-190.19K	-797.48K	-745.57K	-1.58M	-274.64K	-443.17K
Financing Cash Flow	502.12K	1.96M	2.58M	6.29M	4.08M	2.60M	2.09M	2.04M	5.08M	9.50M	-1.74M	6.79M	1.60M
Capital Expenditure	107.85K	63.51K	233.13K	548.46K	154.07K	27.34K	984	70.96K	29.67K	20.09K	291.36K	519.88K	472.49K
Free Cash Flow	-767.54K	-1.96M	-2.54M	-2.33M	-6.63M	-2.19M	-2.40M	-1.99M	-2.53M	-3.70M	-2.69M	-5.08M	-2.99M
FCF to OCF	116.35%	103.36%	110.09%	130.82%	102.38%	101.26%	100.04%	103.71%	101.19%	100.55%	112.15%	111.39%	118.75%

Key Statistics & Ratios

Market Cap51.36M

Enterprise Value54.11M

Trailing P/E0.00

Forward P/E0.00

Price / Sales3.54

Price / Book2.41

EPS-0.11

Book Value0.593

Revenue (TTM)14.52M

Gross Profit (TTM)11.94M

EBITDA-2.60M

Profit Margin-24.76%

Operating Margin-29.69%

Return on Equity-15.89%

Return on Assets-7.54%

Shares Outstanding35.91M

Shares Float10.87M

Beta0.03

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%